Lung cancer breakthrough: drug combination cuts death risk by 58% in major trial
A Phase 3 trial found that a combination of tarlatamab (Amgen) and durvalumab (AstraZeneca) reduced death risk by 58% and extended median survival to 21.1 months in extensive-stage small cell lung cancer patients. The study involved 563 patients across 29 countries. Amgen plans regulatory submissions.
How this was made
The 30-second read
Why it matters
The 58% mortality reduction and median OS gain are unprecedented for this disease, likely prompting regulatory submissions and market re‑rating.
Market read
First‑time reporting of pivotal Phase 3 data that could reshape treatment standards and affect biotech equities.
What to watch
Potential competition from lurbinectedin/atezolizumab combos and reimbursement challenges.
Background
The DeLLphi‑305 Phase 3 trial compared tarlatamab + durvalumab versus durvalumab alone in extensive‑stage small‑cell lung cancer.
Ticker impact
Amgen's tarlatamab (Imdelltra) showed a 58% mortality reduction in a Phase 3 small‑cell lung cancer trial.
likely upside as market prices in the survival benefit
Phase 3 results are material and novel; the drug targets an unmet need, prompting potential FDA submission.
AstraZeneca's durvalumab (Imfinzi) combined with tarlatamab achieved a median survival of 21.1 months versus 12.7 months alone.
likely modest upside as investors weigh the benefit against safety profile
The trial demonstrates a clear advantage for the combo, suggesting a future indication expansion.
Market effects
Strengthens the oncology/biotech sector, especially bispecific antibody platforms.
Positive for US biotech markets; may influence European peers developing similar therapies.
Highlights the growing importance of immuno‑oncology advances worldwide.
Counterpoint
High adverse‑event rates and $30k per cycle price could limit adoption and pressure margins.
Key entities
- CompanyAmgen
Developer of tarlatamab (Imdelltra).
- CompanyAstraZeneca
Developer of durvalumab (Imfinzi).
